Similar articles

• Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Sorensen PS, Bertolotto A. Sorensen PS, et al. Neurology. 2007 Oct 9;69(15):1552; author reply 1553. doi: 10.1212/01.wnl.0000285763.31151.a6. Neurology. 2007. PMID: 17923618 No abstract available.
• Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Pachner AR. Pachner AR. Neurology. 2007 Oct 9;69(15):1555; author reply 1565. doi: 10.1212/01.wnl.0000295672.17358.95. Neurology. 2007. PMID: 17923620 No abstract available.
• Interferon neutralizing antibodies in multiple sclerosis: a new perspective.

  Phillips JT. Phillips JT. Arch Neurol. 2010 Apr;67(4):386-7. doi: 10.1001/archneurol.2010.31. Arch Neurol. 2010. PMID: 20385901 No abstract available.
• Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS, et al. Neurology. 2008 Sep 2;71(10):766-73. doi: 10.1212/01.wnl.0000320512.21919.d2. Neurology. 2008. PMID: 18765653 Review.
• Interferon-beta1b in multiple sclerosis.

  Buttmann M, Rieckmann P. Buttmann M, et al. Expert Rev Neurother. 2007 Mar;7(3):227-39. doi: 10.1586/14737175.7.3.227. Expert Rev Neurother. 2007. PMID: 17341170 Review.